iRhythm Technologies, Inc.

As of October 24, 2025, iRhythm Technologies, Inc. has a mildly bullish trend supported by monthly bullish signals, despite some weekly bearish indicators, and has outperformed the S&P 500 year-to-date with a 100.30% return, though it has underperformed over the past five years with a -17.96% return.

As of October 24, 2025, iRhythm Technologies, Inc. shows a mildly bullish trend overall, supported by strong monthly indicators and daily moving averages, despite mixed signals from weekly metrics.

As of October 24, 2025, iRhythm Technologies, Inc. has shifted to a mildly bullish trend, supported by monthly bullish indicators despite some weekly bearish signals, and has significantly outperformed the S&P 500 year-to-date and over the past year, though it has underperformed over the 3-year and 5-year periods.

As of August 1, 2025, iRhythm Technologies, Inc. shows a bullish technical trend with strong indicators, including bullish MACD and moving averages, and has outperformed the S&P 500 significantly over the past month and year-to-date.

As of February 15, 2017, iRhythm Technologies, Inc. is considered risky and overvalued due to its high Price to Book Value, negative EV to EBITDA, and poor ROE, despite a strong recent return, as its long-term performance significantly lags behind the S&P 500.

As of February 15, 2017, iRhythm Technologies, Inc. is considered overvalued and risky, with significant financial distress indicated by a Price to Book Value of 54.03, negative P/E ratio of -70.04, and poor ROE of -76.24%, despite outperforming the S&P 500 with a 46.52% return over the past year.

As of May 2, 2025, iRhythm Technologies, Inc. exhibits a strong bullish trend supported by positive MACD, Bollinger Bands, and moving averages across multiple time frames, alongside a 4.24% weekly return that outperforms the S&P 500.

As of March 2022, the management team of iRhythm Technologies, Inc. consists of independent directors, including Mr. Abhijit Talwalkar (Chairman), Mr. Bruce Bodaken, Ms. Renee Budig, Dr. Cathleen Noel Merz, Mr. Mark Rubash, and Mr. Raymond Scott. They provide governance and oversight for the company.

iRhythm Technologies, Inc. is a digital health company specializing in biosensor technology and analytics for patient data, with a market cap of approximately $4.63 billion. As of March 2025, it reported net sales of $159 million and a net loss of $31 million.

As of Jun 18, iRhythm Technologies, Inc. has a market capitalization of $4.63 billion, with net sales of $618.59 million and a net profit of -$98.32 million over the latest four quarters. The company reported shareholder's funds of $90.91 million and total assets of $931.45 million as of Dec 24.